Gynecology Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 4.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Gynecology Drugs Market Analysis
The Gynecology Drugs Market is expected to register a CAGR of 4.5% during the forecast period.
Key growth drivers in the market under study are the escalating burden of gynecological diseases, a growing healthcare awareness, and a rising population of aging women. The increasing prevalence of conditions such as ovarian cancer, uterine fibroids, and endometriosis necessitates advanced medical interventions. Additionally, heightened awareness about women's health issues and preventive care has led to more frequent medical consultations and screenings. The aging female demographic further contributes to market growth, as older women are more susceptible to gynecological conditions, increasing the demand for healthcare services and products.
The increasing prevalence of gynecological diseases is expected to persist, spurring the need for effective treatments. This, in turn, propels the global market for gynecological drugs during the forecast period. According to the Australian Institutes of Health and Welfare, in October 2023, endometriosis accounted for 8,213 years of lived with disability (YLD) in 2023. The highest burden of this disease falls on women aged 30–34, with a rate of 1.71 YLD per 1,000 females. Notably, the YLD rate for endometriosis surged by 40% from 2003 to 2023, even after accounting for changes in the age demographic. Thus, the increasing burden of endometritis is expected to increase demand for treatment with gynecology drugs during the forecast period.
Similarly, the high prevalence of gynecology cancers is expected to propel the demand for gynecology drugs, thereby propelling the market growth. For instance, BGI Genomics 2023 Global State of Cervical Cancer Awareness Report. Cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases in 2023. Further, Globocan's 2022 projections anticipate a 55% increase in global ovarian cancer diagnoses among women, reaching 503,448 by 2050. Thus, the high burden of gynecological cancer, such as cervical and ovarian cancer, is anticipated to increase the need for effective treatment, thereby boosting the market's growth.
Moreover, the rising developments by key market players also enhanced the market's growth. For instance, in April 2024, Pfizer Inc. and Genmab AS declared that the Food and Drug Administration (FDA) approved TIVDAK (nivolumab vedotin-tftv) through the supplemental Biologics License Application (sBLA). This approval is specifically for treating patients facing recurrent or metastatic cervical cancer whose condition has worsened post-chemotherapy. Similarly, in September 2022, Lynparza received approval in China as the first line of maintenance treatment with bevacizumab for homologous recombination deficiency (HRD)-positive advanced ovarian cancer.
Thus, the growing burden of gynecological diseases and gynecological cancer and product launches by the market players is expected to contribute to the market's growth during the forecast period. However, the high cost and stringent regulatory framework that delays the approval of products are likely to restrain the market's growth during the forecast period.
Gynecology Drugs Market Trends
The Non-hormonal Therapy Segment is Expected to Witness High Growth During the Forecast Period
The non-hormonal therapy segment is expected to have a high growth rate during the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment, rapid advancements in new product development with reduced side effects, and the availability of a wide range of marketed products. Furthermore, the disadvantages of hormonal therapy, such as the risk of breast cancer and other complications associated with these products, are expected to foster the demand for non-hormonal products during the forecast period.
Various studies are being conducted to measure the effectiveness and advantages of non-hormonal therapy. For instance, according to the study published by PubMed in March 2022, NLRP3/IL-1β is involved in the pathogenesis of endometriosis, and the NLRP3 inhibitor may be useful for suppressing ovarian endometriosis and improving the function of ovaries with endometriosis. Thus, significant benefits associated with non-hormonal therapy in gynecological diseases are expected to contribute to the segment's growth during the forecast period.
In addition, increasing clinical trials and launching new non-hormonal therapy drugs for various symptoms are also surging the segment's growth. For instance, in May 2023, Astellas Pharma Inc. announced that the United States Food and Drug Administration (FDA) approved VEOZAHTM (fezolinetant) 45 mg for daily use. This approval is specifically for treating moderate to severe vasomotor symptoms (VMS) resulting from menopause. VEOZAH marks a significant milestone as the inaugural non-hormonal neurokinin 3 (NK3) receptor antagonist is sanctioned for this purpose.
Therefore, increasing studies on non-hormonal therapy and clinical trials are expected to increase awareness of the application of non-hormonal therapy in treating gynecological cancers. Hence, significant segment growth is anticipated during the forecast period.
North America is Expected to Hold a Significant Share in the Market
North America is expected to hold a significant share of the gynecology drugs market during the forecast period. The market is driven by the rising incidences of breast cancer, menopausal disorders, polycystic ovary syndrome, and others due to busy lifestyles and the rise in stress among women in the region.
Moreover, the availability of advanced healthcare infrastructure, an increase in government expenditure for women's healthcare awareness, and the senior women population, along with early product launches with enhanced quality in the region, are expected to contribute to the market's growth during the forecast period.
The growing burden of gynecological diseases in the region is expected to increase demand for effective treatment options, thereby boosting the market's growth. For instance, as per the report published by the Canadian Cancer Society in May 2024, it was estimated that around 1,450 Canadian women would be diagnosed with cervical cancer in 2022. Further, according to the American Cancer Society 2024 report, an estimated 13,820 people in the United States are expected to be diagnosed with invasive cervical cancer in 2024. Thus, the high burden of gynecological cancer among individuals in the United States and Canada is expected to increase demand for gynecological drugs, thereby contributing to the growth of the market during the forecast period.
Key product launches, high concentration of market players or manufacturers' presence, acquisition, and & partnerships among major players are expected to propel the market's growth over the forecast period. For instance, in May 2024, Bayer released data from two advanced-stage studies on elinzanetant, designed to address severe vasomotor symptoms in menopausal women, particularly hot flashes, directly challenging Astellas' established treatment, Veozah. Similarly, in February 2023, GSK PLC announced that the United States Food Drug Administration (FDA) granted full approval for Jemperli to treat adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer.
Such high prevalence and launch of drug treatment is anticipated to surge the demand for gynecology drugs, thereby propelling the market's growth in the United States during the forecast period.
Gynecology Drugs Industry Overview
The gynecology drugs market is semi-consolidated and consists of several major players. Some prominent players in the market are implementing various strategies, such as launching new products and making acquisitions to consolidate their market positions across the world. The competitive landscape includes an analysis of a few international and local companies that hold the market shares and are well known, including Allergan PLC, Pfizer Inc., AbbVie Inc., TherapeuticsMD Inc., and Ferring Holding SA.
Gynecology Drugs Market Leaders
-
Ferring Holding SA
-
TherapeuticsMD Inc.
-
AbbVie Inc.
-
Pfizer Inc.
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
Gynecology Drugs Market News
- March 2024: Debiopharm announced the first patient dosed in the expansion of its open-label, non-randomized, multicenter Phase 1 study evaluating Debio 0123, an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor, as a monotherapy in patients with recurrent or progressive solid tumors and gynecological cancers.
- January 2024: BioNTech SE and Duality Biologics (Suzhou) Co. Ltd revealed that the US Food and Drug Administration (FDA) gave Fast Track designation upon BNT325/DB-1305. This designation is aimed at expediting the development and review process for the treatment of patients diagnosed with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. These patients should have undergone one to three systemic treatment regimens prior.
Gynecology Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Gynecological Diseases
4.2.2 Rise in Healthcare Awareness Along with Increasing Ageing Female Population
4.3 Market Restraints
4.3.1 High Costs and Stringent Regulatory Framework that Delays the Approval of the Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Therapeutics
5.1.1 Hormonal Therapy
5.1.2 Non-hormonal Therapy
5.2 By Indication
5.2.1 Gynecology Cancers
5.2.2 Menopausal Disorder
5.2.3 Polycystic Ovary Syndrome
5.2.4 Contraception
5.2.5 Other Indications
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 AbbVie Inc.
6.1.3 TherapeuticsMD Inc.
6.1.4 Ferring Holding SA
6.1.5 Lupin Pharmaceuticals Inc.
6.1.6 Johnson & Johnson
6.1.7 Eli Lilly and Company
6.1.8 Bayer AG
6.1.9 GSK PLC
6.1.10 Abbott Laboratories Ltd
6.1.11 AstraZeneca
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Gynecology Drugs Industry Segmentation
Gynecological drugs are used to treat ailments related to the female reproductive system. A major shift in the lifestyles of women led to a rise in the prevalence of gynecological disorders affecting the functioning of the uterus, ovaries, and appendages.
The gynecology drugs market is segmented by therapeutics, indication, distribution channel, and geography. By therapeutics, the market is segmented as hormonal therapy and non-hormonal therapy). By indication, the market is segmented as gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception, and other indications. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America).
The report offers the value (USD) for the above segments.
| By Therapeutics | |
| Hormonal Therapy | |
| Non-hormonal Therapy |
| By Indication | |
| Gynecology Cancers | |
| Menopausal Disorder | |
| Polycystic Ovary Syndrome | |
| Contraception | |
| Other Indications |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gynecology Drugs Market Research FAQs
What is the current Gynecology Drugs Market size?
The Gynecology Drugs Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)
Who are the key players in Gynecology Drugs Market?
Ferring Holding SA, TherapeuticsMD Inc., AbbVie Inc., Pfizer Inc. and GSK plc are the major companies operating in the Gynecology Drugs Market.
Which is the fastest growing region in Gynecology Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Gynecology Drugs Market?
In 2024, the North America accounts for the largest market share in Gynecology Drugs Market.
What years does this Gynecology Drugs Market cover?
The report covers the Gynecology Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Gynecology Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Gynecological Drugs Industry Report
Statistics for the 2024 Gynecological Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gynecological Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
